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Abstract
Codon-optimized genes were synthesized for the SIVmac239 Gag, a mutant Gag with mutations in the major homology region, and a chimeric
Gag containing a protein destruction signal at the N-terminus of Gag. The mutant and chimeric Gag were expressed at levels comparable to that
observed for the wild-type Gag protein but their stability and release into the medium were found to be significantly reduced. Immunization of mice
with DNA vectors encoding the mutant or chimeric Gag induced fourfold higher levels of anti-SIV Gag CD4 T cell responses than the DNA vector
encoding the wild-type SIV Gag. Moreover, anti-SIV Gag CD8 T cell responses induced by DNA vectors encoding the mutant or chimeric Gag
were found to be 5- to 10-fold higher than those induced by the DNA construct for the wild-type Gag. These results indicate that mutations
disrupting assembly and/or stability of the SIV Gag protein effectively enhance its immunogenicity when expressed from DNA vaccines.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
An effective AIDS vaccine should be able to induce
strong neutralizing antibody responses as well as cellular
immune responses against HIV antigens. Many studies have
shown that strong cytotoxic T lymphocyte (CTL) immune
responses play an important role in the control of HIV
infection and replication. Evidence obtained over the last
decade has shown that the emergence of strong antiviral
CTL responses has been associated with a reduction of
viremia during acute infection by HIV or SIV (Borrow et
al., 1994; Chen et al., 1995; Koup et al., 1994; Schmitz et
al., 1999), suggesting that a strong CTL immune response is
able to control HIV and SIV infection and replication
(Brander and Walker, 1999; Picker, 2000). Furthermore,
HIV-infected individuals with strong CTL immune re-
sponses are more likely to become long-term nonprogres-
sors with no symptoms and low or undetectable plasma
virus (Carmichael et al., 1993; Edwards et al., 2002; Klain
et al., 1995; Ogg et al., 1998; Rinaldo et al., 1995; Rosen-
berg et al., 1997). Consistent with these studies, it is gen-
erally accepted that an effective AIDS vaccine should pos-
sess the ability to induce strong cellular immune responses
along with neutralizing antibody responses against HIV
antigens (Goulder et al., 1999; Robinson et al., 2000). It has
been shown that the ability of the DNA vaccines to prime
immunized animals for a CTL response plays a critical role
in the induction of strong and long-lasting CTL responses
and the successful protection against subsequent challenge
(Barouch et al., 2000, 2001; Gurunathan et al., 2000). Re-
cently, it was reported that immunization of rhesus monkeys
with a DNA vaccine followed by boosting with a modified
vaccinia recombinant expressing the same SHIV antigens
gave promising results in protection against subsequent
challenge (Amara et al., 2001). Similarly, Shiver et al.,
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(2002) showed that a replication-incompetent adenoviral
vector expressing SIV Gag was able to elicit strong anti-SIV
CTL responses in immunized monkeys which conferred
control of viremia and disease development. Successful
protection of immunized monkeys against subsequent infec-
tion has been attributed to the strong CTL immune response
induced by immunization protocols used in these studies.
The Gag protein of HIV and SIV is a major viral com-
ponent, relatively conserved in comparison to the Env pro-
tein, and one of the major targets of cellular immune re-
sponse. The Gag protein is synthesized in the cytoplasm and
released from the cell through budding at the plasma mem-
brane after assembling into particles (Freed, 1998). The
efficient assembly and release of the Gag protein may re-
duce its availability for intracellular degradation by the
proteasome complex in the cytoplasm for efficient presen-
tation by the MHC I molecules (Coux et al., 1996; Goldberg
and Rock, 1992; Groettrup et al., 1996). In this study, we
compared two alternative approaches to disrupt assembly
and release of the SIV Gag protein, by introducing muta-
tions in its major homology region (MHR) (Mammano et al.,
1994) as well as fusing the Gag protein to a protein destruction
signal of the encephalomyocarditis virus (EMCV) 3C protease
(Lawson et al., 1999). Immunogenicity of DNA constructs
expressing wild-type as well as mutant SIV Gag proteins
were evaluated in mice. We have compared the wild-type
and mutant Gag proteins that are assembly-defective with
respect to their intracellular stability as well as their ability
to elicit cellular immune responses against the SIV Gag.
Results
The mutant SIV Gag protein and the 3C/Gag chimeric
protein exhibit reduced stability and impaired ability to
assemble and release from the cell
The SIV Gag protein, similar to other retrovirus Gag
proteins, is synthesized in the cytoplasm, modified by myri-
stylation and targeted to the inner surface of the plasma
membrane, and released into the medium through assembly
into particles and budding (Freed, 1998). We hypothesized
that the efficient assembly and release of the Gag protein
may affect its processing and presentation by antigen-pre-
senting cells for induction of cellular immune responses. To
test our hypothesis, we constructed the gene for a mutant
SIV Gag protein (Gag-M) with mutations in its MHR that
have been shown to affect virus assembly (Mammano et al.,
1994). Furthermore, previous studies by Lawson et al.,
(1999) showed that a segment in the EMCV 3C protease is
responsible for its rapid intracellular degradation. By intro-
ducing this signal to the poliovirus 3C protease, an other-
wise stable protein, the chimeric protein becomes a good
substrate for degradation by the ubiquitin system and is
rapidly degraded after synthesis. To investigate whether the
3C protease protein destruction signal can be employed to
enhance intracellular degradation of the SIV Gag protein
and to augment its immunogenicity, we also synthesized the
gene for a 3C/Gag chimeric protein in which the coding
sequence for the 3C signal was inserted into the SHIV89.6
gag gene after its methionine start codon. Shown in Fig. 1
is a schematic diagram for the design of the mutant and
chimeric SIV Gag proteins.
Several groups have shown that DNA constructs con-
taining synthesized genes with codons optimized for mam-
malian usage give higher levels of protein expression and
induce stronger immune response in immunized animals
(Andre et al., 1998; Deml et al., 2001; Haas et al., 1996; zur
Megede et al., 2000; Uchijima et al., 1998). Therefore, we
synthesized codon-optimized genes for the wild-type SIV-
mac239 Gag, the mutant Gag-M, and the 3C/Gag chimeric
proteins as described under Materials and methods. The
genes were cloned into plasmid vector pCAGGS under the
control of the chicken -actin promoter. In vitro expression,
release into the medium, and stability of the proteins were
analyzed by transfection of HeLa cells with DNA con-
structs. As shown in Fig. 2A, by labeling with [35S]Met,
Cys-labeling mix followed with immunoprecipitation and
SDS–PAGE analysis, we found that all proteins were ex-
pressed at high levels in transfected HeLa cells. However,
the release of the mutant Gag-M was significantly reduced,
while release of the chimeric 3C/Gag was greatly impaired.
This is not surprising since release of Gag is mostly via
assembly and budding through the plasma membrane and in
the 3C/Gag chimeric protein, the myristylation site (the Gly
residue at position 2 of the wild-type Gag protein), which is
necessary for Gag protein association with the membrane
and assembly was eliminated by insertion of the 3C protein
destruction signal (Bryant and Ratner, 1990; Morikara et al.,
1996). Furthermore, as shown in Fig. 2B, the mutant Gag-M
also exhibited a faster degradation rate (especially when
reduction in Gag-M release is also taken into consideration)
and degradation of the chimeric 3C/Gag was significantly
increased. Electron microscopy studies also showed that the
mutant Gag-M and the chimeric 3C/Gag failed to assemble
into virus-like particles (data not shown). These results
showed that mutation in the SIV Gag MHR or insertion of
Fig. 1. Schematic diagram of SIV Gag, the mutant Gag-M, and 3C/Gag
chimeric proteins. Codon-optimized genes for Gag, Gag-M, and 3C/gag
were synthesized as described under Materials and methods. Black boxes
represent the 3C protein destruction signal sequence (shown below, under-
lined). Amino acids shown in Gag indicate the mutations in the Gag MHR
for Gag-M (Q288 to A and E292 to D).
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the 3C segment at its N-terminus reduced its efficient re-
lease and its intracellular stability, with a more pronounced
effect observed for the chimeric 3C/Gag.
The DNA construct for the mutant Gag-M induces higher
levels of cellular immune responses than the DNA
construct for wild-type Gag
To investigate the effect of mutations in the SIV Gag
MHR which were found to reduce release as well as stabil-
ity of the Gag protein on its immunogenicity, we immu-
nized mice using these DNA constructs and evaluated cel-
lular immune response by intracellular cytokine staining
and flow cytometry. Splenocytes from mice immunized
with DNA constructs were prepared, pooled, and stimulated
with four peptide pools that cover the entire SIV Gag
protein (pool 1, aa 151–284; pool 2, aa 1–162; pool 3, aa
273–413; and pool 4, aa 402–513). After stimulation, cells
were stained for surface CD4 and CD8 as well as intracel-
lular interferon- (IFN). The results are shown in Fig. 3
(for CD8 T cell responses) and Fig. 4 (for CD4 T cell
responses). As shown in Fig. 3, the levels of IFN-produc-
ing CD8 T cells from SIV/Gag immunized mice after stim-
ulation by each peptide pool were only moderately higher
than those from control DNA vector (pCAGGS) immunized
mice. This result indicates that only weak CD8 T cell
responses against the SIV Gag protein were induced in mice
immunized with the DNA construct encoding the wild-type
SIV Gag protein. Immunization of mice with the SIV Gag
DNA construct also induced CD4 T cell responses against
the SIV Gag protein (Fig. 4), although the levels of re-
sponses are also low, with about 0.1 to 0.2% of CD4 T cells
producing IFN upon stimulation with each peptide pool,
respectively. On the other hand, immunization of mice with
the DNA construct for the mutant Gag-M induced higher
levels of CD8 T cell response against the SIV Gag protein.
As shown in Fig. 3, the percentages of IFN-producing
CD8 T cells from Gag-M-immunized mice were about 0.8,
0.5, and 0.4% upon stimulation with peptide pool 2, 3, and
4, respectively, two- to fourfold higher than those induced
by immunization with the Gag DNA construct. Moreover,
the levels of CD4 T cell responses from Gag-M-immunized
mice were also increased, with approximately 0.2, 0.8, 0.8,
0.7% of CD4 T cells producing IFN upon stimulation with
peptide pools 1, 2, 3, and 4, respectively. These results indi-
cate that mutations disrupting assembly and release of the SIV
Gag protein enhance its immunogenicity in the context of
DNA immunization.
Immunization of mice with the DNA construct for the 3C/
Gag chimeric protein induced more potent CD8 T cell
responses against the SIV Gag protein
As shown in Fig. 2, while mutations in the SIV Gag MHR
were found to affect its assembly, release, and degradation rate
as observed for the mutant Gag-M, the effects exerted by
insertion of the 3C segment into the N-terminus of the SIV
Gag proteins were more pronounced. Also, as shown by the
results presented above, the DNA construct encoding the mu-
tant Gag-M exhibits superior immunogenicity compared to the
DNA construct for the wild-type SIV Gag protein. We rea-
soned that if the improved immunogenicity of Gag-M results
from the observed phenotype of the mutant Gag-M, i.e., im-
pairment in assembly and release into the medium and de-
crease in stability, then the DNA construct for the 3C/Gag
chimeric protein which is more severely impaired in these
properties would be expected to be more effective in inducing
cellular immune responses against the SIV Gag protein. To test
this hypothesis, we also immunized mice with the 3C/Gag
DNA construct using the same immunization protocol. As
shown in Fig. 5, while the levels of CD4 T cell responses
induced by the chimeric 3C/Gag DNA construct are compa-
rable to those induced by the mutant Gag-M construct, the
levels of CD8 T cell responses induced by the chimeric 3C/
Gag construct were higher, most notably upon stimulation by
peptide pool 3, for which the percentage of IFN-producing
CD8 T cells increased by over three fold (2.6 compared to
0.8%) compared to the level of CD8 T cell responses induced
by immunization with the Gag-M construct. These results
show that the DNA construct for the 3C/Gag chimeric protein
exhibits enhanced ability to induce CD8 T cell responses.
Comparison of immune responses by enzyme-linked
immunosorbent spot (ELISPOT) assay
We also compared immune responses induced by immu-
nization with different Gag DNA constructs by ELISPOT
Fig. 2. (A) Expression and release of the SIV mac239, Gag, the MHR mutant
Gag-M, and the chimeric 3C/Gag proteins. HeLa cells were transfected with
DNA constructs for 48 h and labeled with [35S]Met,Cys-labeling mix for 4 h.
Supernatant and cell lysates were subjected to immunoprecipitation with anti-
SIV serum plus Protein A agarose beads. (B) Stability of wild-type Gag,
mutant Gag-M, and chimeric 3C/Gag proteins. Duplicate sets of HeLa cells
were transfected with DNA constructs for 48 h and one set was radioactively
labeled for 30 min (pulse) and the other set was labeled for 30 min and then
chased in complete medium for an additional 4 h. Lane 1: plasmid vector
pCAGGS; lane 2: Gag; lane 3: Gag-M; lane 4: 3C/Gag.
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assay, an alternative sensitive assay to evaluate cellular
immune response without differentiating cell phenotypes
(Lalvani et al., 1997). As shown in Fig. 6, both DNA
constructs for the mutant Gag-M and the chimeric 3C/Gag
induced higher levels of immune responses (total of about
400 and 1000 spots per million cells for Gag-M and 3C/Gag
immunized mice, respectively) than the DNA construct for
the wild-type Gag (total of about 200 spots per million
Fig. 3. Intracellular cytokine staining and flow cytometry analysis of CD8 T cell responses induced by immunization with DNA constructs for wild-type Gag
and mutant Gag-M. Mice (five per group) were immunized with indicated DNA construct as described in the text. Mouse splenocytes from each group were
pooled and the pooled splenocytes aliquots (2  106 per well in a 48-well plate) were stimulated for 16 h using each of the four peptide pools (22 to 25 mers
overlapping by 12 amino acids: Pool 1, aa 151–284; pool 2, aa 1–162; pool 3, aa 273–413; and pool 4, aa 402–513) covering the entire SIV Gag protein,
followed by addition of brefeldin A and a further incubation of 5 h and then stained for surface CD4 (FITC) and CD8 (PerCP) and intracellular IFN (PE).
(A) Gating of lymphocytes by front and side scattering and IFN production by lymphocytes stimulated with peptide IGPRARYAR (Control). (B) IFN
production by CD8 T cells stimulated with different peptide pools. Numbers in boxes represent percentages of IFN staining positive CD8 T cells.
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cells). Splenocytes from control vector pCAGGS immu-
nized mice only produced background numbers of spots
after stimulation with each peptide pool (less than 20 total
spots per million cells), similar to the number of spots
detected in the absence of peptide pool stimulation (data not
shown). These results parallel those obtained by ICC stain-
ing and flow cytometry, indicating that the DNA constructs
expressing mutant Gag-M or chimeric 3C/Gag are more
potent immunogens. Also, in agreement with ICC staining
and flow cytometry analysis, immunization with the DNA
construct for the wild-type Gag induced low but detectable
cellular immune responses against SIV Gag, about 200 total
number of spots for splenocytes from the Gag DNA con-
struct immunized mice vs less than 20 total spots for spleno-
cytes from pCAGGS DNA-immunized mice.
Discussion
In this study, we synthesized codon-optimized genes for
wild-type and mutant SIV Gag proteins as well as a 3C/Gag
chimeric protein and evaluated their immunogenicity in
mice. Both CD4 and CD8 T cell responses were quantita-
tively analyzed by intracellular cytokine (ICC) staining and
flow cytometry. As summarized in Fig. 7, immunization
with the DNA constructs for the assembly-defective mutant
Gag and the 3C/Gag chimeric protein induced CD8 T cell
responses against the SIV Gag protein, whereas only very
low levels of CD8 T cell responses were induced in mice
immunized with DNA constructs encoding assembly-com-
petent SIV Gag proteins. Furthermore, the DNA construct
for the 3C/Gag chimeric protein that is more severely im-
paired for release and stability also induced higher levels of
anti-SIV Gag CD8 T cell responses. More interestingly,
immunization with DNA constructs expressing the assem-
bly-defective mutant SIV Gag-M and the chimeric 3C/Gag
proteins also induced fourfold higher levels of CD4 T cell
responses in comparison to DNA constructs encoding the
wild-type SIV Gag protein, and enhanced CD4 T cell re-
sponses were observed for splenocytes stimulated with all
four peptide pools covering the entire SIV Gag protein
sequence. Since both the mutant Gag-M protein and the
3C/Gag chimeric protein are defective in assembly and
release and exhibit reduced stability, these results indicate
Fig. 4. Intracellular cytokine staining and flow cytometry analysis of CD4 T cell responses induced by immunization with DNA constructs for wild-type Gag
and mutant Gag-M. Mice (five per group) were immunized with indicated DNA construct as described in text. Mouse splenocytes from each group were
pooled and stimulated using each of the four peptide pools and then stained for surface CD4 and CD8 and intracellular IFN as described in Fig. 3. Numbers
in boxes represent the percentages of IFN staining positive CD4 T cells stimulated with different peptide pools. Gating of lymphocytes by front and side
scattering and IFN production by lymphocytes stimulated with peptide IGPRARYAR (Control) are shown in Fig. 3.
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that DNA vaccines expressing assembly-defective Gag pro-
teins with increased intracellular degradation are more po-
tent immunogens for eliciting cellular immune responses.
A number of studies have shown that DNA vaccines can
effectively induce both cellular and humoral immune re-
sponses against their encoded antigens (Gurunathan et al.,
2000). This feature of DNA immunization is highly desir-
able for developing effective vaccines against HIV infec-
tion, which requires both cellular and humoral immune
responses (Letvin et al., 2001; Nabel, 2001). Our results
show that DNA constructs encoding mutant or chimeric SIV
Gag proteins with reduced stability and impaired ability for
assembly induced stronger CD8 T cell against the SIV Gag
protein, and enhancement was observed in all four peptide
pools covering the entire Gag sequence. However, CD8 T
cell responses stimulated by peptide pool 1 were consider-
ably lower in comparison to stimulation by other peptide
pools, possibly due to the lack of a strong CD8 epitope in
the region covered by peptide pool 1. One possible mech-
anism for the observed enhancement is that reduced release
from the cell and increased intracellular degradation pro-
vides more Gag proteins for processing and presentation by
the MHC I molecules in antigen presenting cells, which in
turn stimulated higher levels of CD8 T cell responses. In-
duction of CTL immune responses is mediated through
presentation of foreign antigens by the MHC I molecules in
antigen-presenting cells (Harty et al., 2000; Pamer and
Cresswell, 1998), which in general requires antigen degra-
dation by the proteasome complex in the cytoplasm (Coux
et al., 1996; Goldberg and Rock, 1992; Groettrup et al.,
1996). The peptides generated by cytoplasmic antigen deg-
radation are then translocated into the lumen of the ER by
the TAP transporters and loaded onto newly synthesized
MHC I molecules (Kelly et al., 1992; Neefjes et al., 1993).
Therefore, enhancement of protein degradation in the cyto-
plasm could potentially facilitate antigen presentation by
MHC I molecules (Grant et al., 1995; Hershko and Ciech-
anover, 1998). Similar results using other approaches have
been obtained in early studies for HIV Nef, influenza NP, as
well as LCMV NP proteins (Tobery and Siliciano, 1997;
Fig. 5. Cellular immune responses against SIV Gag antigen induced by immunization with the DNA construct for the 3C/Gag chimeric protein. Mice (five
per group) were immunized with the 3C/Gag DNA construct as described in the text. Mouse splenocytes were pooled and stimulated for 16 h using each
of the four peptide pools and then stained for surface CD4 and CD8 and intracellular IFN as described in Fig. 3. (A) Percentages of IFN staining positive
CD8 T cells in mouse splenocytes stimulated with different peptide pools. (B) Percentages of IFN staining positive CD4 T cells in mouse splenocytes
stimulated with different peptide pools. Gating of lymphocytes by front and side scattering and IFN production by lymphocytes stimulated with peptide
IGPRARYAR (Control) are shown in Fig. 3.
Fig. 6. IFN production from splenocytes determined by ELISPOT assay.
Splenocytes from each group of mice immunized with indicated DNA
constructs were pooled and the pooled splenocytes aliquots (106 per well)
were seeded into ELISPOT plates and stimulated for 16 h using each of the
four peptide pools. IFN-producing cells (spots) were detected and counted
as described under Materials and methods.
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Townsend et al., 1988; Rodriguez et al., 1997), and it has
been suggested that increased intracellular degradation of
these proteins leads to more efficient processing and pre-
sentation. Interestingly, although both mutants (Gag-M and
3C/Gag) elicited higher levels of CD8 T cell responses, the
magnitude of enhancement with respect to stimulation by
each peptide pool was found to be different for these two
mutants. Notably, mutant Gag-M induced higher levels of
CD8 T cell responses as stimulated by the peptide pool 2,
whereas enhancement of CD8 T cell response by 3C/Gag
was more pronounced when stimulated by the peptide pool
3. It will be interesting in future studies to determine which
mutant elicits CD8 T cell responses which are more relevant
to the naturally processed wild-type SIV Gag protein, and
therefore, are more suitable for a more potent AIDS vac-
cine. Nonetheless, our results show that both of the two Gag
modification approaches are effective in enhancing induc-
tion of cellular immune responses, suggesting that introduc-
ing proteins to intracellular degradation may offer a broad
application for enhancing immunogenicity.
We also observed that immunization with DNA con-
structs expressing mutant and 3C/Gag chimeric proteins
induced higher levels of CD4 T cell responses. However,
the mechanism for the enhanced CD4 T cell response re-
mains to be determined. Although the mechanism presented
above is likely to be responsible for the stronger CD8 T cell
responses induced by Gag-M and 3C/Gag DNA constructs
against the SIV Gag protein, it does not explain the obser-
vation that immunization with these constructs also induced
enhanced CD4 T cell responses, which in general requires
protein degradation in lysosomes or endosomes for presen-
tation by MHC II molecules. It is possible that accumulation
of the mutant or chimeric Gag proteins in the cytoplasm will
form aggregates that could be engulfed by lysosomes by
autophagocytosis (Holtzman, 1989). Also, modifications of
the Gag may render it more susceptible for degradation and
processing by cellular machineries. Although the role of
CD4 T cells in the control of HIV infection and replication
is still unclear, several studies reported that HIV-specific
CD4 T cells also showed direct antigen-specific cytotoxic
activity (Curiel et al., 1993; Norris et al., 2001; Rosenberg
et al., 1997; Venturini et al., 2002). Furthermore, a strong
CD4 T cell response has been shown to play important roles
in maintaining functional viral-specific CD8 T cell re-
sponses as well as induction of neutralizing antibodies (Ciu-
rea et al., 2001; Matloubian et al., 1994; Planz et al., 1997;
Zajac et al., 1998). Moreover, it has been reported that while
CD4 T helper cells are not required for induction of CTL
responses against dominant epitopes with strong affinity for
MHC I molecules, they are critical in priming CTL re-
sponses against subdominant epitopes with weaker affinity
for MHC I molecules (Franco et al., 2000). Therefore, the
enhanced CD4 T cell responses induced by the mutant Gag
DNA constructs may also be responsible for the induction
of enhanced CD8 T cell responses, which are observed in all
four regions covered by each peptide pool. Induction of
strong CD4 T cell responses and CD8 T cell responses
against subdominant epitopes of HIV antigens may be par-
ticularly important for an effective AIDS vaccine, in light of
a recent report showing that SHIV mutant escaping from
immune responses against a dominant epitope in Gag arise
in vaccinated animals after challenge (Barouch et al., 2002).
It will be interesting to determine in future studies whether
similar approaches can also be applied to other antigens or
different vaccine modalities for inducing enhanced cellular
immune responses in nonhuman primate models and
whether induction of a broader response may confer more
effective protection against viral infection.
Materials and methods
Synthesis of codon-optimized genes for SIV Gag, mutant
SIV Gag, and 3C/Gag chimeric proteins
Synthetic genes for wild-type as well as mutant SIV-
mac239 Gag proteins with codons optimized for mamma-
lian usage were synthesized by PCR assembly of long
Fig. 7. Summary of cellular immune responses induced by immunization with different DNA constructs. (A) Percentage of IFN staining positive CD8 T
cells in mouse splenocytes stimulated with different peptide pools. (B) Percentage of IFN staining positive CD4 T cells in mouse splenocytes stimulated
with different peptide pools. (C) Percentage of total (sums of four peptide pools) IFN staining positive CD4 and CD8 T cells in mouse splenocytes stimulated
with peptide pools.
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single-strand DNA templates (100 bases in length) as de-
scribed by Haas et al. (1996). A synthetic DNA encoding
the 14 amino acid EMCV 3C protease destruction signal
was also synthesized similarly and fused in-frame to the 5-
end of the synthetic gene for SIV Gag to generate the gene
for the 3C/Gag chimeric protein. The sequences of the
synthetic genes were confirmed by sequencing and then
cloned into a plasmid vector pCAGGS (kindly provided by
Dr. Y. Kawaoka) under the control of the chicken -actin
promoter.
Analysis of protein expression
Protein expression was analyzed by radioactively label-
ing and immunoprecipitation followed by SDS–PAGE.
HeLa cells were transfected with plasmid vectors by Lipo-
fectamine 2000 (GIBCO-BRL) following the manufactur-
er’s protocol. At 36 h posttransfection, cells were starved in
Met,Cys-deficient DMEM for 30 min and then labeled with
[35S] Met,Cys cell labeling mix (Amersham) for 30 min.
The cells were then chased in complete medium (DMEM
plus 10% fetal calf serum) for an additional 3 h before being
lysed with lysis buffer and precipitated with antiserum
against SIVmac239 and Protein A agarose beads (Pierce).
Protein samples were then prepared and analyzed by SDS–
PAGE.
Immunization of mice
Female BALB/c mice (H-2d) 6–8 weeks of age were
purchased from Charles River Laboratory. Plasmids were
amplified in Escherichia coli DH5 and purified with a
Qiagen Endo-Free Megaprep kit. The plasmids were then
resuspended at 1 g/l in sterile PBS and stored at 80°C
until used for immunization. For each immunization study,
groups of mice (five mice per group) were immunized with
a total of 100 g DNA per mouse by intramuscular injection
with 50 l DNA preparation in separate sites in both side
quadriceps, followed by boosting with the same dose of
DNA at week 4 and week 8.
Flow cytometry analysis of immune responses
At 14 days after the final DNA immunization, mice were
sacrificed and spleens were removed, homogenized, and
compressed through a sterile nylon membrane. Mouse
splenocytes were prepared by lysis of red blood cells with
ammonium chloride and washed twice with RPMI 1640.
The cells were resuspended in complete culture medium
(RPMI 1640 plus 10% fetal calf serum, 50 M -mercap-
toethanol, and antibiotics mix) and the cell viability was
determined by trypan blue exclusion. Cells (106) were cul-
tured with pools of peptide (20 to 22 mers overlapping by
10 amino acids) corresponding to the SIVmac239 Gag pro-
tein (kindly provided by Dr. Harriet L. Robinson, Yerkes
Primate Center, Emory University) for 16 h and then added
with brefeldin A (Sigma, 10 g/ml) and incubated for ad-
ditional 5 h. Cells cultured with PMA plus ionomycin were
used as positive controls, whereas cells cultured with an
irrelevant peptide (IGPRARYAR) corresponding to an
H-2d-restricted CTL epitope for HIV Env protein were used
as negative controls. After stimulation, the cells were
washed twice with PBS containing 3% fetal calf serum and
then stained with FITC-conjugated rat anti-mouse CD4 and
PerCP-conjugated rat anti-mouse CD8 antibodies (Pharm-
ingen). Cells were then fixed and permeabilized with cytofix
buffers (Caltag) and then stained for intracellular IFN
using PE-conjugated rat anti-mouse IFN antibody (Pharm-
ingen). Flow cytometry analysis was performed on a BD
FACSCalibre with CELLQuest software.
ELISPOTs assay
A purified rat anti-mouse IFN monoclonal antibody
R4-6A2 (PharMingen) was used to coat Multiscreen 96-
well filtration plates (Millipore, Bedford, MA) at 4 g/ml in
PBS at 4°C overnight. Coated plates were washed with
0.05% Tween 20 in PBS (PBST) before 200 l of 10% FCS
in RPMI 1640 was added to each well for 2 h at 37°C to
block nonspecific binding. Freshly prepared splenocytes (1
 106 cells) in 100 l of complete medium with or without
peptide pools were placed in each well and incubated at
37°C for 24 h. Plates were washed with PBST and overlaid
with 50 l (2 g/ml) of biotinylated anti-mouse IFN
monoclonal antibody (XMG1.2, Pharmingen) 24 h at 4°C.
The plates were then washed six times with PBST and
treated with avidin-conjugated with horseradish peroxidase
(HRP) (Pharmingen) at 1:1000 dilution for 2 h at RT. After
extensive washing, stable DAB (Research Genetics) was
added to develop spots in the plates for 30 min. The plates
were rinsed with water and air dried and the spots were
counted in an ImmunoSpot ELISpot reader (Cellular Tech-
nology).
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